Comparative Pharmacology
Head-to-head clinical analysis: CERINTA versus FOUNDAYO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERINTA versus FOUNDAYO.
CERINTA vs FOUNDAYO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); enhances serotonergic neurotransmission by inhibiting serotonin reuptake at the presynaptic neuron.
Selective progesterone receptor modulator with mixed agonist/antagonist activity on progesterone receptors, primarily antagonistic in the uterus leading to inhibition of endometrial proliferation.
50 mg orally twice daily
100 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10–14 h) in adults; prolonged to 24–30 h in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 3-4 hours in healthy adults; prolonged to 6-8 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 12 hours in severe renal impairment (CrCl <30 mL/min).
Renal (70% unchanged) and fecal (25% as metabolites); biliary excretion minimal (<5%).
Primarily renal (80-90% as unchanged drug), with 10-20% fecal via biliary excretion. Less than 5% metabolized.
Category C
Category C
Oral contraceptive
Oral contraceptive